Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD). (Q52898427)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 February 2011

Language	Label	Description	Also known as
English	Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).	scientific article published on 3 February 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD). (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michele Colledan

4

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

author name string

Eugenia Giraldi

1

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

Massimo Provenzi

2

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

Roberto Fiocchi

3

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

Pieremilio Cornelli

5

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

Giuliano Torre

6

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

Alessandro Rambaldi

7

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

Valentino Conter

8

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

publication date

3 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

Pediatric Blood Cancer

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

57

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

2

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

324-328

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Treatment of PTLD with rituximab or chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Hematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Lymphomas occurring late after solid-organ transplantation

1 reference

https://api.crossref.org/works/10.1002%2FPBC.23004

21 January 2018

Identifiers

10.1002/PBC.23004

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21294246

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52898427&oldid=1561067184"